Development of Epstein-Barr Virus-related Primary Diffuse Large B-cell Lymphoma of the Central Nervous System in a Patient with Peripheral T-cell Lymphoma, Not Otherwise Specified after Mogamulizumab Treatment

Mogamulizumab is a defucosylated humanized anti-CC chemokine receptor type 4 (CCR4) antibody that exerts an anti-tumor immune effect against various tumors through a suppressive effect on regulatory T-cells. We herein report a patient with peripheral T-cell lymphoma who developed Epstein-Barr virus (EBV)-related primary diffuse large B-cell lymphoma of the central nervous system (CNS DLBCL) after mogamulizumab therapy. Our experience should alert physicians to the possibility of the development of EBV-related CNS DLBCL in patients treated for primary lymphoma and suggests that the anti-tumor immune effect of mogamulizumab is ineffective for the prophylaxis of EBV-related lymphomas.

[1]  Kenji Matsumoto,et al.  Cytomegalovirus Pneumonia after Anti-CC-chemokine Receptor 4 Monoclonal Antibody (Mogamulizumab) Therapy in an Angioimmunoblastic T-cell Lymphoma Patient. , 2016, Internal medicine.

[2]  H. Masuzaki,et al.  Fatal pneumonia and viremia due to human parainfluenza virus type 1 in a patient with adult T-cell leukemia–lymphoma treated with mogamulizumab , 2015, Journal of Infection and Chemotherapy.

[3]  R. Ueda,et al.  Dose‐intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T‐cell leukaemia‐lymphoma: a randomized phase II study , 2015, British journal of haematology.

[4]  S. Iida,et al.  Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia–lymphoma patients with resolved HBV infection following systemic chemotherapy , 2015, International Journal of Hematology.

[5]  A. Mahadevan,et al.  Primary central nervous system diffuse large B-cell lymphoma in the immunocompetent: Immunophenotypic subtypes and Epstein-Barr virus association , 2015, Journal of neurosciences in rural practice.

[6]  M. Taniwaki,et al.  Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Takahiro Kumode,et al.  Induction of molecular remission by using anti-CC-chemokine receptor 4 (anti-CCR4) antibodies for adult T-cell leukemia: a risk of opportunistic infection after treatment with anti-CCR4 antibodies , 2014, Retrovirology.

[8]  R. Ueda,et al.  Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Iida,et al.  Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rγnull mouse model , 2008, Cancer Immunology, Immunotherapy.

[10]  Sudeep Gupta,et al.  Primary diffuse large B‐cell lymphoma of the tonsil , 2007, Cancer.

[11]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[12]  K. Chang,et al.  Brain lymphomas of immunocompetent and immunocompromised patients: study of the association with Epstein-Barr virus. , 1993, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.